(Reuters) - Gritstone bio Inc said on Tuesday it had entered right into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness improvements (CEPI) to boost its vaccine application against COVID-19 variants, sending its shares up 2.6% earlier than the bell.
Gritstone's vaccine is according to self-amplifying mRNA know-how, which makes use of the body's own machinery to make antigenic protein in place of injecting the antigen into the body.
beneath the contract, CEPI, which co-leads the COVAX vaccine sharing facility, will fund an early stage examine evaluating the application's vaccine in convalescent, and HIV superb sufferers.
The trial is expected to beginning earlier than the conclusion of 2021, Gritstone observed.
CEPI and Gritstone have agreed the vaccine candidate will be made available to the COVAX facility.
(Reporting via Dania Nadeem in Bengaluru; modifying by Vinay Dwivedi)
0 Comments